Crystalline and amorphous carvedilol-loaded nanoemulsions: Formulation optimisation using response surface methodology

Journal of Experimental Nanoscience

Volumn 8, Issue 7-8, 2013, Pages 971-992

  Bhagat, Chandralekha ^a   Singh, Sandeep Kumar ^a   Verma, Priya Ranjan Prasad ^a   Singh, Neeru ^a   Verma, Samridhi ^a   Ahsan, Mohd Neyaz ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

carvedilol; nanoemulsions; response surface methodology; scanning electron microscopy; transmission electron microscopy

Indexed keywords

CARVEDILOL; FORMULATION OPTIMISATION; FUNCTIONAL RELATIONSHIP; INSTRUMENTAL TECHNIQUES; NANO-EMULSIONS; OPERATING VARIABLES; OPTIMAL FORMULATION; RESPONSE SURFACE METHODOLOGY;

EMULSIONS; OPTIMIZATION; POLYDISPERSITY; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTIES; TRANSMISSION ELECTRON MICROSCOPY; ELECTRON MICROSCOPY; EMULSIFICATION; PARTICLE SIZE;

CRYSTALLINE MATERIALS;

BUFFER; CARVEDILOL; CATION; CREMOPHOR; NANOCRYSTAL; OCTANOIN; PHOSPHATE; WATER;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DISTILLATION; DRUG FORMULATION; DRUG MIXTURE; FACTORIAL DESIGN; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; NANOEMULSION; PARTICLE SIZE; PH; PRECIPITATION; PRIORITY JOURNAL; RESPONSE SURFACE METHOD; RESPONSE VARIABLE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG RELEASE; INFRARED SPECTROSCOPY; PARAMETERS; POLYDISPERSIBILITY INDEX; STATISTICAL ANALYSIS; X RAY DIFFRACTION;

EID: 84888073945     PISSN: 17458080     EISSN: 17458099     Source Type: Journal    
DOI: 10.1080/17458080.2011.630037     Document Type: Article

References (31)

1. Horter, D and Dressman, J B. 2001. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug. Delivery. Rev., 46: 75 - 87. doi: 10.1016/S0169-409X(00)00130-7
2. Karavas, E, Georgarakis, M, Docoslis, A and Bikiaris, D. 2007. Combining SEM, TEM, and Raman techniques to differentiate between the amorphous molecular level dispersions and nanodispersions of a poorly water-soluble drug within a polymer matrix. Int. J. Pharm., 340: 76 - 83. doi: 10.1016/j.ijpharm.2007.03.037
3. Aungst, B J. 1993. Novel formulations strategies for improving oral bioavailability of drugs with poor permeability or presystemic metabolism. J. Pharm. Sci., 82: 979 - 987. doi: 10.1002/jps.2600821002
4. Kommuru, T R, Gurley, B, Khan, M A and Reddy, I K. 2001. Self emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. Int. J. Pharm., 21: 233 - 246. doi: 10.1016/S0378-5173(00)00614-1
5. Robinson, J R. 1996. Semi-solid formulations for oral drug delivery. Bull. Tech. Gattefosse., 89: 11 - 13.
6. Singh, S K, Verma, P RP and Razdan, B. 2010. Glibenclamide-loaded self-nanoemulsifying drug delivery system: Development and characterization. Drug. Dev. Ind. Pharm., 36: 933 - 945. doi: 10.3109/03639040903585143
7. Craig, D QM. 2002. The mechanisms of drug release from solid dispersions in watersoluble polymers. Int. J. Pharm., 231: 131 - 144. doi: 10.1016/S0378-5173(01)00891-2
8. Leuner, C and Dressman, J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm., 50: 47 - 60. doi: 10.1016/S0939-6411(00)00076-X
9. Kaloegeras, I M. 2011. A novel approach for analyzing glass-transition temperature vs. composition patterns: Application to pharmaceutical compound + polymers systems. Eur. J. Pharm. Sci., 42: 470 - 483. doi: 10.1016/j.ejps.2011.02.003
10. Vasconcelos, T, Sarmento, B and Costa, P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug. Discov. Today, 12: 1068 - 1075. doi: 10.1016/j.drudis.2007.09.005
11. Van den Mooter, G, Wuyts, M, Blaton, N, Busson, R, Grobet, P, Augustijns, P and Kinget, R. 2001. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci., 12: 261 - 269. doi: 10.1016/S0928-0987(00)00173-1
12. Pokharkar, V B, Mandpe, L P, Padamwar, M N, Ambike, A A, Mahadik, K R and Paradkar, A. 2006. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol., 167: 20 - 25. doi: 10.1016/j.powtec.2006.05.012
13. Singh, S K, Verma, P RP and Razdan, B. 2010. Development and characterization of a lovastatin loaded self-microemulsifying drug delivery system. Pharm. Dev. Technol., 15: 469 - 483. doi: 10.3109/10837450903286537
14. Ruffolo, RR Jr, Gellai, M, Hieble, J P, Willette, R N and Nichols, A J. 1990. The pharmacology of carvedilol. Eur. J. Clin. Pharmacol., 38: S82 - S88. doi: 10.1007/BF01409471
15. Van Zwieten, P A. 1993. Pharmacodynamic profile of carvedilol. Cardiology, 82: 19 - 23. doi: 10.1159/000175939
16. Colucci, W S, Packer, M, Bristow, M R, Gilbert, E M, Cohn, J N, Fowler, M B, Krueger, S K, Hershberger, R, Uretsky, B F, Bowers, J A, Sackner-Bernstein, J D, Young, S T, Holcslaw, T L and Lukas, M A. 1996. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation, 94: 2800 - 2806. doi: 10.1161/01.CIR.94.11.2800
17. Packer, M, Bristow, M R, Cohn, J N, Colucci, W S, Fowler, M B, Gilbert, E M and Shusteman, N H. 1996. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med., 334: 1349 - 1355. doi: 10.1056/NEJM199605233342101
18. Planinsek, O, Kovacic, B and Vrecer, F. 2011. Carvedilol dissolution improvement by preparation of solid dispersions with porous silica. Int. J. Pharm., 406: 41 - 48. doi: 10.1016/j.ijpharm.2010.12.035
19. Brook, C S, Chen, W and Spoors, P G. 2007, Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment, US Patent 7,268,156
20. Neugebauer, G, Akpan, W, Kaufmann, B and Reiff, K. 1990. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur. J. Clin. Pharmacol., 38: S108 - S111. doi: 10.1007/BF01409476
21. Morgan, T. 1994. Clinicalpharmacokinetics and pharmacodynamics of carvedilol. Clin. Pharmacokinet., 26: 335 - 346. doi: 10.2165/00003088-199426050-00002
22. Singh, S K, Verma, P RP and Razdan, B. 2009. Development and characterization of a carvedilol-loaded self-microemulsifying delivery system. Clin. Res. Regul. Aff., 26: 50 - 64. doi: 10.1080/10601330903143942
23. Chen, B P and Chow, M SS. 1997. Focus on carvedilol: A novel beta-adrenergic blocking agent for the treatment of congestive heart failure. Formulary, 32: 795 - 805.
24. Gohel, M C and Amin, A F. 1998. Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. J. Controlled Release, 51: 115 - 122. doi: 10.1016/S0168-3659(97)00102-8
25. Box, G and Wilson, K B. 1951. On the experimental attainment of optimum conditions. J. R. Stat. Soc., Ser. B. Methodol., 13: 1 - 45.
26. Bhavsar, M D, Tiwari, S B and Amji, M A. 2006. Formulation optimization for nanoparticles-in-microspheres hybrid oral delivery system using factorial design. J. Controlled Release, 110: 422 - 430. doi: 10.1016/j.jconrel.2005.11.001
27. Li, W, Nadig, D, Rasmussen, H, Patel, K and Shah, T. 2005. Sample preparation optimization for assay of active pharmaceutical ingredients in a transdermal drug delivery system using experimental designs. J. Pharm. Biomed. Anal., 37: 493 - 498. doi: 10.1016/j.jpba.2004.11.033
28. El-Gibaly, I and Abdel-Ghaffar, S. 2005. Effect of hexacosanol on the characteristics of novel sustained-release allopurinol solid lipospheres (SLS): Factorial design application and product evaluation. Int. J. Pharm., 294: 33 - 51. doi: 10.1016/j.ijpharm.2004.12.027
29. Lammel, A, Schwab, M, Hofer, M, Winter, G and Scheibel, T. 2011. Recombinant spider silk particles as drug delivery vehicles. Biomaterials, 32: 2233 - 2240. doi: 10.1016/j.biomaterials.2010.11.060
30. Kang, B K, Lee, J S, Chon, S K, Jeong, S Y, Yuk, S H, Khang, G, Lee, H B and Cho, S H. 2004. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pharm., 274: 65 - 73. doi: 10.1016/j.ijpharm.2003.12.028
31. Basalious, E B, Shawky, N and Badr-Eldin, S M. 2010. SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine I: Development and optimization. Int. J. Pharm., 391: 203 - 211. doi: 10.1016/j.ijpharm.2010.03.008